FDA Grants RMAT Designation to Atsena Therapeutics’ Gene Therapy for X-linked Retinoschisis
The designation aims to expedite development of ATSN-201 for X-linked retinoschisis, a rare inherited retinal disease with no approved treatment.The…
BREAKING: Ascidian’s RNA Exon Editor for Stargardt Disease Makes Historic First in Gene Therapy
The first clinical-stage RNA exon editor in the world – which is being applied first to eye care – just…